Literature DB >> 12135848

Spectrum and antibiotic resistance of uropathogens from hospitalized patients with urinary tract infections: 1994-2000.

F M E Wagenlehner1, A Niemetz, A Dalhoff, K G Naber.   

Abstract

During the period 1994-2000 all uropathogens cultured from urine of hospitalized urological patients were identified and susceptibility was tested against 11 antibacterials. Duplicated isolates were eliminated. There was no general trend of increased of resistance apart from E. coli to ciprofloxacin (10.4% in 2000). Vancomycin-resistant staphylococci or enterococci was not significant. The lowest overall rates of resistance were found with piperacillin/tazobactam followed by ciprofloxacin and trimethoprim/sulphamethoxazole. Ciprofloxacin was the best oral antibiotic for the empirical treatment of urinary tract infection (UTI) due to Gram-negative rods and ampicillin/sulbactam for the treatment of UTI with Gram-positive cocci.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12135848     DOI: 10.1016/s0924-8579(02)00100-0

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  13 in total

Review 1.  The emerging threat of multidrug-resistant Gram-negative bacteria in urology.

Authors:  Hosam M Zowawi; Patrick N A Harris; Matthew J Roberts; Paul A Tambyah; Mark A Schembri; M Diletta Pezzani; Deborah A Williamson; David L Paterson
Journal:  Nat Rev Urol       Date:  2015-09-01       Impact factor: 14.432

2.  Urinary bactericidal activity of extended-release ciprofloxacin (1,000 milligrams) versus levofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose.

Authors:  Florian M E Wagenlehner; Martina Kinzig-Schippers; Uwe Tischmeyer; Christine Wagenlehner; Fritz Sörgel; Kurt G Naber
Journal:  Antimicrob Agents Chemother       Date:  2006-09-18       Impact factor: 5.191

3.  [Infections of the urinary tract and male genitalia].

Authors:  W Weidner; K G Naber; A G Hofstetter; M Ludwig; W Vahlensieck; F M E Wagenlehner; P Schneede
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

4.  [Nosocomial urinary tract infections in the geriatric hospital - pathogen spectrum and resistancies].

Authors:  R Thiesemann; E-U Walter; I Füsgen
Journal:  Z Gerontol Geriatr       Date:  2008-03-11       Impact factor: 1.281

Review 5.  [Nosocomial urinary tract infection in adults].

Authors:  B L Hug; U Flückiger; A F Widmer
Journal:  Internist (Berl)       Date:  2006-11       Impact factor: 0.743

6.  Antibiotic resistance in E. coli isolates from patients with urinary tract infections presenting to the emergency department.

Authors:  Florian Hitzenbichler; Michaela Simon; Thomas Holzmann; Michael Iberer; Markus Zimmermann; Bernd Salzberger; Frank Hanses
Journal:  Infection       Date:  2018-01-24       Impact factor: 3.553

Review 7.  Asymptomatic bacteriuria in elderly patients: significance and implications for treatment.

Authors:  Florian M E Wagenlehner; Kurt G Naber; Wolfgang Weidner
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

8.  The bacterial insertion sequence element IS256 occurs preferentially in nosocomial Staphylococcus epidermidis isolates: association with biofilm formation and resistance to aminoglycosides.

Authors:  Svetlana Kozitskaya; Seung-Hak Cho; Katja Dietrich; Reinhard Marre; Kurt Naber; Wilma Ziebuhr
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

9.  Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the global prevalence of infections in urology study.

Authors:  Zafer Tandogdu; Mete Cek; Florian Wagenlehner; Kurt Naber; Peter Tenke; Edgar van Ostrum; Truls Bjerklund Johansen
Journal:  World J Urol       Date:  2013-08-24       Impact factor: 4.226

10.  The assessment of Proteus mirabilis susceptibility to ceftazidime and ciprofloxacin and the impact of these antibiotics at subinhibitory concentrations on Proteus mirabilis biofilms.

Authors:  Joanna Kwiecińska-Piróg; Krzysztof Skowron; Katarzyna Zniszczol; Eugenia Gospodarek
Journal:  Biomed Res Int       Date:  2013-09-12       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.